The Chinese Pharmaceuticals Market to 2024

Product code:CHI1

Availability: In stock

€1,799.00

Qty: Buy Now - OR -

The Chinese Pharmaceutical Market to 2024


Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024


Released 19/3/2014

160 Pages

140 Tables, Charts and Graphs



-         Capture or increase your foothold in the Chinese market TODAY

-         Establish partnerships to manufacture, distribute or develop Chinese products

-         Establish anti-counterfeiting systems today to increase market size and revenue

 

From 2008 to 2013, China’s OTC drugs market reported an average growth of 15% with the market reaching $20.6bn in 2013 up from to $11bn in 2008 - but what will it be this year? Next year? and in 5 years time?

 

The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you.

 

China’s pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably.  Have you captured enough of the Chinese market?

 

Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY.

 

Anti-Counterfeiting and anti-corruption – How the Chinese market is changing

Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.

 

Increased inward investment from multiple ‘Big Pharma’ companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel.

 

Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market.

 

  • Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011
  • Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015
  • In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure.
  • Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases
  • The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008
 

This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment.

  

Discover exactly what the industry leaders are doing TODAY -  

 

Industry information sourced exclusively for this report. This information is not available anywhere else

 

Utilising primary and secondary research sources, GMR Data have interviewed leading specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations specialising in access to the Chinese market, as well as Chinese pharmaceutical companies accessing the global market. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

 

This GMR Data report is the single tool to equip you with the latest trends in all pharma sectors and why all stakeholders demand development of the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.

 

With over 160 pages, and over 140+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

 

To order this report please contact Alice Morgan on TEL: +353 86 075 2687 or by emailing Alice.Morgan@GMRData.com

 

1. Executive Summary

1.1. Chinese Pharmaceutical Market Review

1.2. Chapter Breakdown

1.3. Research and Analysis Methods

 

 

2. Drivers & Restraints of the Chinese Pharmaceutical Market

2.1 An Ageing Population will drive pharmaceutical market growth in China

2.2 Increase in Chinese urbanisation

2.3 Increase in Healthcare expenditure will increase drug demand in China

2.4 Government policies and changing environment for MNCs in China

2.5 Increased demand for improved drug quality

2.6 Healthcare Reform in China

2.7 Path to privatization of Chinese healthcare

2.8 Consolidation of the pharmaceutical distribution industry in China

2.9 Increase in lifestyle related diseases

2.10 Biotechnology Market: The Strategic Industry for China

2.11 Focus on GMP leads to Quality and Compliance reforms

2.12 Government led initiatives to attract foreign players

2.13 Talent Pool Availability

2.14 Increased Outsourcing of Drug Discovery boosting the Chinese CRO Market

2.15 Regulatory Environment

2.15.1 Drug filing

2.15.2 Advertisements

2.15.3 Drugs Pricing & Reimbursement

2.16 Traditional Chinese Medicine

 

        

3. China Pharmaceutical Market Forecast

3.1 Chinese Pharmaceutical Market; Pharmaceutical Sales (OTC and Prescription market)

3.1.1 Chinese pharmaceutical sales market Forecast 2008-2024

3.1.2 China Pharmaceutical Sales Market by Generic and Patented Drug Sales

3.1.3 Generic Drugs Market in China

3.2 The Chinese Patented Drugs Market           

3.3 China Pharmaceutical Sales Market by Prescription and OTC Drug Sales

3.3.1 Prescription Drug Market in China

3.3.2 Over-the-Counter Drugs Market in China

 

 

4. The Chinese Medical Device Market

4.1 Overview of  the Medical Device Market in China

4.2 China Medical Devices Market: Diagnostic Imaging Segment

4.3 China Medical Devices Market: Patient Aids Segment

4.4 China Medical Devices Market: Consumables Segment

4.5 The China Medical Devices Market: Dental Segment

4.6 China Medical Devices Market: Orthopaedic Segment

4.7 Challenges & Opportunities in the Medical devices market

4.7.1 Opportunities

4.7.2 Challenges

4.8 China Medical Devices Market: Players Landscape

4.8.1 Multinational Corporations in the Chinese Medical devices market

4.8.1.1 General Electric Healthcare

4.8.1.1 Medtronic, Inc.

4.8.1.2 Zimmer - Zimmer Holdings, Inc.

4.8.1.3 Stryker Corporation

4.8.1.4 Siemens Healthcare

4.8.1.5 Johnson & Johnson

4.8.1.6 Philips Healthcare (Suzhou) Co., Ltd

4.9 Key Domestic companies in the Chinese Medical devices market

4.9.1 Weigao group

4.9.2 Mindray Medical International Limited

4.9.3 MicroPort Scientific Corporation

4.9.4 Biosensors International Group, Ltd

 

 

                                                        

5. The Chinese API Market

5.1 API Overview

5.1.1 Global API Market

5.1.1.1 APAC API Market

5.1.1.2 The Chinese API Market

5.2 Major Growth Drivers for the Chinese API Market

5.3 Key Challenges

5.4 China API Market: Players Landscape

5.4.1 Major Chinese API Manufacturers

5.4.1.1 Zhejiang Hisun Pharmaceutical Co. Ltd

5.4.1.2  Jiangsu Hengrui Medicine Co., Ltd

5.4.1.3 CSPC Pharmaceutical Group Limited

5.4.1.4   Shandong Xinhua Pharmaceutical Company Limited

5.4.1.5 Shanghai Pharma Holding Company Limited

5.4.1.6 North China Pharmaceutical Group Corp.

 

 

6 Key Chinese Therapeutic Markets

6.1 Cardiovascular Diseases

6.1.1 Chinese Cardiovascular Disease treatments market forecast 2014-2024

6.2 Infectious Diseases

6.2.1 Chinese Infectious Disease treatments market forecast 2014-2024

6.3 Oncology  

6.3.1 Chinese Oncology treatments market forecast 2014-2024

6.4 Nervous System

6.4.1 The Chinese Nervous System market forecast 2014-2024

6.5 Alimentary Tract & Metabolism  

6.5.1 The Chinese Alimentary Tract & Metabolism treatments market forecast 2014-2024

 

 

7. Major Players

7.1 Pfizer

7.2. Bayer

7.3. Sanofi-Aventis

7.4. AstraZeneca

7.5. Roche

7.6. Merck and Co.

7.7. Novartis

7.8. GSK        

7.9. Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.)

 

 

8. Expert Opinion

8.1 Dr Cezary Statuch – Vice President Bristol-Myers Squibb, China

8.2 Dr Eugene Buff – Primary Care Innovation Consulting & UsTech Discovery LLC

 

 

 

 

 

 

 

 

 

 

List of Tables

 

Table 2.1.1: Percentage of Chinese population aged 60 and over / 65 and over in 2000, 2011 & 2016

Table 2.1.2: Health spending in China, India and the US, 2009 & 2011 ($/p/a & percentage change)

Table 2.1.3: Total Health Expenditure (as % of GDP); Selected Countries 2004 to 2011

Table 2.1.4: Life expectancy; Selected Countries 2004 to 2011

Table 2.2.1 Medical Coverage for Rural / Urban inhabitants in China 2006 / 2009 (million people)

Table 2.2.2: Major cities in China by population (2011)

Table 2.3.1 China’s Health Care Expenditure Per Capita 2003-2011

Table 2.6.1: Key New Drugs on the 2012 Essential Drugs List

Table 2.8.1: Total Revenue of Key Chinese Pharmaceutical Distribution Companies, 2012 ($/bn)

Table 2.9.1: Number of Patients with Diabetes in China

Table 2.15.3.1 China healthcare payment source breakdown 2000, 2005 & 2010 (%)

Table 3.1.1.1: China Pharmaceutical Sales Market Size: 2008-2013 ($bn)

Table 3.1.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 ($bn)

Table 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013

Table 3.1.3.2: China’s Generic Drug Sales Market Forecast 2014-2024 ($bn)

Table 3.2.1: China Parented Drug Sales Market Size: 2008-2013

Table 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 ($bn)

Table 3.3.1.1: China Prescription Drugs Sales Market Size: 2008-2013

Table 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024

Table 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013

Table 3.3.2.2 China’s OTC Drug Sales Percentage 2013

Table 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024

Table 4.a:  The Chinese Medical Devices Market Forecast 2014 -2024, by device type ($/bn)

Table 4.b:   Key Device Segments CAGR 2014-2024 (%)

Table 4.c: Estimated China Medical Devices Market Share for Selected Segments 2014, 2019 and 2024 (%)

Table 4.1.1: China Medical Devices Market Size: 2008-2013

Table 4.1.2: China Medical Devices Export Market 2009-2011 ($/bn)

Table 4.1.3: China Medical Devices Import Market

Table 4.1.4: China Medical Devices Market Forecast 2014-2024 ($bn)

Table 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013 ($/bn)

Table 4.2.2: China Medical Devices Market: Diagnostic Imaging Segment Forecast 2014-2024 ($/bn)

Table 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 ($/bn)

Table 4.3.2: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 ($/bn)

Table 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013 ($/bn)

Table 4.4.2: The Chinese Medical Devices Market: Consumables Segment Forecast 2014-2024 ($ bn)

Table 4.5.1: China Medical Devices Market: Dental Segment 2008-2013

Table 4.5.2: China Medical Devices Market: Dental Segment Forecast 2014-2024 ($m)

Table 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013

Table 4.6.2: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 ($m)

Table 5.1:  China API Market Forecast 2014 -2024, compared to Global API Market ($ bn)

Table 5.1.1.: China API Market Size: 2009-2013

Table 5.1.2: China API Market Forecast 2014-2024 ($bn)

Table 6.a:  China Pharmaceutical Market by Therapeutic Areas 2014 -2024, ($ bn)

Table 6.b:   Key Therapeutic Areas CAGR 2014-2024 (%)

Table 6.c: Estimated China Pharmaceutical Market Share by Therapeutic Areas - 2014, 2019 and 2024 (%)

Table 6.1.1: Cardiovascular Disease Incidence China 2010 – 2013

Table 6.1.2: Deaths due to Cardiovascular Disease in India, China and Developed Markets

Table 6.1.3: China Pharmaceutical Market for Cardiovascular Disease, 2008 – 2013 ($/bn)

Table 6.1.4: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 – 2024

Table 6.2.1: Infectious Disease Incidence 2010 – 2013

Table 6.2.2: Infectious Disease Mortality 2010 – 2013

Table 6.2.3: China Pharmaceutical Market for Systemic Anti-Infective, 2008 – 2013

Table 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 – 2024

Table 6.3.1: Cancer Incidence China 2010 – 2013

Table 6.3.2: Cancer Mortalities 2010 – 2013

Table 6.3.3: China Pharmaceutical Market for Oncology, 2008 – 2013

Table 6.3.4: China Pharmaceutical Market for Oncology: Forecast 2014 – 2024

Table 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 – 2013

Table 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 – 2024

Table 6.5.1: China Pharmaceutical Market for Metabolism, 2008 – 2013

Table 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 – 2024

 

 

List of Figures

 

Figure 2.1.1: China population growth trend 1950-2013

Figure 2.1.2: Projected comparison of China’s population vs. other heavily populated countries 2016 (million people)

Figure 2.1.3: China’s Age distribution: 2001 to 2011

Figure 2.1.4: Life expectancy in China

Figure 2.2.1: China’s Rural and Urban population from 1990 to 2025 – Billion People

Figure 2.2.2: China’s Urbanisation Rate 1990-2025 (%)

Figure 2.2.3: Per Capita Disposable Income 

Figure 2.3.1: China GDP growth trend (2004 – 2012)

Figure 2.3.2: China’s total health expenditure (as % of GDP): 2004 to 2011

Figure 2.3.3: China healthcare expenditure per capita growth trend (2003 – 2011)

Figure 2.6.1: China’s 2009 health care reform – Healthcare package breakdown

Figure 2.8.1: Chinese pharmaceutical distribution sales: 2006 to 2012

Figure 2.9.1: Number of Patients with Diabetes in 2013 – Globally (million people)

Figure 2.13.1: China’s talent pool in 2010- (in millions)

Figure 2.15.3.1: China healthcare payment source breakdown

Figure 3.1.1: China Pharmaceutical Sales Market Size: 2008-2013

Figure 3.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 ($bn)

Figure 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013

Figure 3.1.3.2: China’s Generic Drug Sales Market Forecast 2014-2024 ($ bn)

Figure 3.2.1: China Patented Drug Sales Market Size: 2008-2013

Figure 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 ($ bn)

Figure 3.3.1.1: China Prescription Drug Sales Market Size: 2008-2013

Figure 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024

Figure 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013

Figure 3.3.2.2 OTC drugs Channel Breakdown in China 2011

Figure 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024

Figure 4.a: China Medical Devices Market Share for Selected Segments 2014

Figure 4.b: China Medical Devices Market Share for Selected Segments 2019

Figure 4.c: China Medical Devices Market Share for Selected Segments 2024

Figure 4.1.1: China Medical Devices Market Size: 2008-2013

Figure 4.1.2: China Medical Devices Market Forecast 2014-2024 ($bn)

Figure 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013

Figure 4.2.2: China Diagnostic Imaging devices breakdown by sub-segment, 2012 (%)

Figure 4.2.3:  China Medical Devices Market: Diagnostics Segment Forecast 2014-2024 ($bn)

Figure 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 ($/bn)

Figure 4.3.2: 2012 Patient Aids devices breakdown by sub-segment 2012 (%)

Figure 4.3.3:  China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 ($/bn)

Figure 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013

Figure 4.4.2: 2012 Consumables devices breakdown by sub-segment

Figure 4.4.3:  China Medical Devices Market: Consumables Segment Forecast 2014-2024 ($ bn)

Figure 4.5.1: China Medical Devices Market: Dental Segment 2008-2013

Figure 4.5.2: 2012 Dental Devices breakdown by sub-segment, China, 2013

Figure 4.5.3:  China Medical Devices Market: Dental Segment Forecast 2014-2024 ($m)

Figure 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013

Figure 4.6.2: 2012 Orthopaedic Devices breakdown by sub-segment

Figure 4.6.3:  China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 ($m)

Figure 4.8.1.2.1: Medtronic 2012 Customer base breakdown by region

Figure 4.9.1.1: 2012 Customer base breakdown by segment

Figure 4.9.1.2: 2012 Sales revenue breakdown by region

Figure 4.9.1.3: Weigao Group Sales revenue breakdown by product segment 2012 (%)

Figure 4.9.2.1: 2012 Sales revenue breakdown by region

Figure 4.9.2.2: 2012 Sales revenue breakdown by product

Figure 4.9.3.1: 2012 Sales revenue breakdown by product (%)

Figure 4.9.4.1: 2012 Sales revenue breakdown by product (%)

Figure 5.1.1.1: Breakdown of API Manufacturing 2012

Figure 5.1.1.2.1: China API Market Size: 2009-2013

Figure 5.1.1.2.2: China API Market Breakdown 2013

Figure 5.1.1.2.3: China API Market Forecast 2014-2024 ($bn)

Figure 6.a: China Pharmaceutical Market Share by Therapeutic Areas 2014

Figure 6.b: China Pharmaceutical Market Share by Therapeutic Areas 2019

Figure 6.c: China Pharmaceutical Market Share by Therapeutic Areas 2024

Figure 6.1.1: Cardiovascular Disease Incidence 2010 – 2013

Figure 6.1.2: China Pharmaceutical Market for Cardiovascular Disease, 2008 – 2013 ($/bn)

Figure 6.1.3: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 – 2024

Figure 6.2.1: Infectious Disease Incidence 2010 – 2013

Figure 6.2.2: Infectious Disease Mortality 2010 – 2013

Figure 6.2.3: Mortality as per Infectious Diseases, China 2012

Figure 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective, 2008 – 2013

Figure 6.2.5: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 – 2024

Figure 6.3.1: Cancer Deaths in China / Hong Kong, 2011

Figure 6.3.2: China Pharmaceutical Market for Oncology, 2008 – 2013

Figure 6.3.3: China Pharmaceutical Market for Oncology: Forecast 2014 – 2024

Figure 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 – 2013

Figure 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 – 2024

Figure 6.5.1: China Pharmaceutical Market for Metabolism, 2008 – 2013

Figure 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 – 2024

Figure 7.9.1 Novo Nordisk’s sales of diabetes products in China, 2012Contents

 

 

 

 

Companies Mentioned in this report

 

Abbott Laboratories and Takeda Pharmaceutical Co Ltd

Alcon

Alliance Boots GmbH

Amgen

Ascendancy Healthcare

Ascletis

AstraZeneca

Bayer Healthcare

BeiGene Ltd

Beijing Drug Administration

Beijing Montagne Medical Device Co., Ltd

Beijing Percil Instrument

Beijing University

BioMatrix

Biosensors Europe S.A.

Biosensors International Group, Ltd.

BMS

Boehringer Ingelheim 

Celsion

Changzhou Kony Pharmaceutical Co., Ltd

Changzhou Pharmaceutical Incorporated

Charles River

China Resources Double Crane Pharmaceutical Co., Ltd

China Resources Sanjiu Pharmaceutical

China Shijiazhuang Pharmaceutical Group Co., Ltd (CSPC)

Ciba - Geigy Pharmaceutical Co., Ltd

Colgate-Palmolive Co

Concord Medical Services Holdings Limited

Covance

CSPC Huasheng Pharma

CSPC XNW Pharmaceutical Joint Stock Co., Ltd

CSPC Zhongrun Pharmaceutical Co. Ltd

Daiichi Sankyo

Dainippon Sumitomo Pharma

Eddingpharm

Eisai China Inc

Eisai Co., Ltd

FibroGen

Fudan University

GE Healthcare

GlaxoSmithKline

Grandhope Biotech

Guangzhou Pharma

Hangzhou East China Pharmaceutical Group

Hangzhou Optcla Medical Instrument

Hangzhou Tigermed Consulting

Harbin Pharmaceutical

Harbin Pharmaceutical Group Holding Co., Ltd

Hawley & Hazel (BVI) Co. Ltd.

Hisor

Hua Medicine Ltd

ICON

Innovation Centre China (ICC)

Ironwood Pharmaceuticals

Japan's Pharmaceuticals and Medical Devices Agency (PMDA)

Jiangsu Hengrui Medicine Co., Ltd

Johnson & Johnson

JOINN Laboratories

Jointown

Journal of Toxicology and Environmental Health

JW MedicalSystems Ltd

Kanghui Holdings

KangHui Medical

Kyowa Hakko Kirin Co.

LifeTech

Livzon Pharmaceutical Group Inc.

Medtronic

Merck & Co.

Merck Sharp & Dohme (China) Co. Ltd

MicroPort Scientific Corporation

Mindray

Nanjing MeiRui Pharma Co.

Nanjing Pharmaceutical Co.

Neptune Interlong Bio-Technique Co. Ltd. (NIBT)

NeuroVive Pharmaceutical AB

North China Pharmaceutical Group Corp (NCPC)

NovaMed

Novartis

Orchid Chemicals and Pharmaceuticals Limited

Peking University

Pfizer

Philips Electronics NV.

Philips Healthcare

Procter & Gamble Co.

ProteoTech

ProteoTech

Qianjin Pharmacy

Qidong Gaitianli Pharmaceutical

Quintiles

Roche

Sanofi- Aventis

SFDA

Shandong University

Shandong Weigao

Shandong Xinhua Pharmaceutical Company Limited

Shanghai Apex Electronics

Shanghai ChemPartner

Shanghai Institutes for Biological Sciences of Chinese Academy of Science

Shanghai Jiaotong University

Shanghai Jinhe Bio-Technology Co., Ltd

Shanghai Medical Optical Instrument

Shanghai New Hongqiao International Medical Center

Shanghai Pharmaceuticals

Shanghai Roche Pharmaceutical Co., Ltd.

Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

ShangPharma

Shenzhen GSK-Neptunus Biologicals Co. Ltd

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd

Shijiazhuang Lerentang Pharmaceutical Co.

Siemens

Siemens Healthcare Diagnostics

Siemens Hearing Instrument (Suzhou)

Siemens Medical Solutions Diagnostics Ltd

Siemens Mindit Magnetic Resonance (SMMR)

Siemens Shanghai Medical Equipment (SSME)

Siemens X-Ray Vacuum Technology (Wuxi)

Sihuan Pharmaceutical Holdings

Simcere Pharmaceutical Group (SCR)

Sino Biological and Pharmaron

Sinopharm

Spectrum Dynamics Medical, Inc.

Stryker

Synthes

Takeda (China) International Trading Co., Ltd

Tasly Group

Tianjin Tasly Pharmaceutical

Topsun Science and Technology

Trauson Holdings

Tsinghua University

Unilever Group

FDA

Vital River

Weihai Medical Polymer Co., Ltd

Wuhan Dragonbio

WuXi Apptec

Wyeth

X-Body Biosciences

Xian Janssen Pharmaceutical Ltd

Xiuzheng Pharmaceutical

Yunnan Baiyao Group

Zhejiang Beta Pharma

Zhejiang Hisun Pharmaceutical Co

Zhejiang Huahai

Zhejiang Tianyuan

Zimmer Holdings Inc.

Zonare Medical Systems